Abstract
We review the current status of imaging as applied to targeted therapy with particular focus on antibody-based therapeutics. Antibodies have high tumor specificity and can be engineered to optimize delivery to, and retention within, the tumor. Whole antibodies can activate natural immune effector mechanisms and can be conjugated to β- and α-emitting radionuclides, toxins, enzymes, and nanoparticles for enhanced therapeutic effect. Imaging is central to the development of these agents and is used for patient selection, performing dosimetry and assessment of response. γ- and positron-emitting radionuclides may be used to image the distribution of antibody-targeted therapeutics While some radionuclides such as iodine-131 emit both β and γ radiation and are therefore suitable for both imaging and therapy, others are more suited to imaging or therapy alone. Hence for radionuclide therapy of neuroendocrine tumors, patients can be selected for therapy on the basis of γ-emitting indium-111-octreotide imaging and treated with β-emitting yttrium-90-octreotate. Positron-emitting radionuclides can give greater sensitivity that γ-emitters but only a single radionuclide can be imaged at one time and the range of radionuclides is more limited. The multiple options for antibody-based therapeutic molecules, imaging technologies and therapeutic scenarios mean that very large amounts of diverse data are being acquired. This can be most effectively shared and progress accelerated by use of common data standards for imaging, biological, and clinical data.
Similar content being viewed by others
References
Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH (1994) Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 21(6):545–559
Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H et al (2003) Uptake of meta-iodobenzylguanidine in neuroendocrine tumors is mediated by vesicular monoamine transporters. Br J Cancer 89(7):1383–1388
Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF et al (2003) 131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumor imaging. Eur J Nucl Med Mol Imaging 30(12):BP132–BP139
Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36(3):228–247
Boersma HH, Wensing JW, Kho TL, de Brauw LM, Liem IH, van Kroonenburgh MJ (2000) Transient enhanced uptake of 123I-metaiodobenzylguanidine in the contralateral adrenal region after resection of an adrenal pheochromocytoma. N Engl J Med 342(19):1450–1451
Leung A, Shapiro B, Hattner R, Kim E, de Kraker J, Ghazzar N et al (1997) Specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 38(9):1352–1357
Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS (2001) 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38(1):6–8
Mangner TJ, Klecker RW, Anderson L, Shields AF (2003) Synthesis of 2′-deoxy-2′-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. Nucl Med Biol 30(3):215–224
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273–282
Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med Mol Imaging 30(5):781–793
Jenkins SA, Kynaston HG, Davies ND, Baxter JN, Nott DM (2001) Somatostatin analogs in oncology: a look to the future. Chemotherapy 47(Suppl 2):162–196
Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ et al (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32(2):110–122
Schillaci O, Massa R, Scopinaro F (2000) 111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 41(3):459–462
Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L et al (1989) Localisation of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1(8632):242–244
Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J (2001) The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumors: a clinical phase II study. Ann Oncol 12(7):941–945
Hejna M, Schmidinger M, Raderer M (2002) The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 13(5):653–668
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23(12):2754–2762
Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M et al (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 31(7):1038–1046
Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H et al (2005) 68 Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32(6):724
Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28(12):1751–1757
Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA et al (2001) 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42(2):213–221
Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B et al (2005) Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90(6):3392–3400
Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S et al (2000) New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 44(1):50–58
Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q et al (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331(17):1116–1121
Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24(4):389–427
Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, de Jong M et al (2000) Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 27(9):1312–1317
Behr TM, Behe MP (2002) Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 32(2):97–109
Hoffman TJ, Gali H, Smith CJ, Sieckman GL, Hayes DL, Owen NK et al (2003) Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 44(5):823–831
Breeman WA, De Jong M, Bernard BF, Kwekkeboom DJ, Srinivasan A, van der Pluijm ME et al (1999) Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 83(5):657–663
Gotthardt M, Fischer M, Naeher I, Holz JB, Jungclas H, Fritsch HW et al (2002) Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging 29(5):597–606
Begent RH, Keep PA, Searle F, Green AJ, Mitchell HD, Jones BE et al (1986) Radioimmunolocalization and selection for surgery in recurrent colorectal cancer. Br J Surg 73(1):64–67
Begent RH, Searle F, Stanway G, Jewkes RF, Jones BE, Vernon P et al (1980) Radioimmunolocalization of tumors by external scintigraphy after administration of 131I antibody to human chorionic gonadotrophin: preliminary communication. J R Soc Med 73(9):624–630
Hitchins RN, Begent RH, Green AJ, Searle F, van Heyningen V, Bagshawe KD (1989) Clinical value of imaging using antibody to alpha fetoprotein in germ cell tumors. Nuklearmedizin 28(1):29–33
Mach JP, Carrel S, Forni M, Ritschard J, Donath A, Alberto P (1980) Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation. N Engl J Med 303(1):5–10
Wu AM, Yazaki PJ (2000) Designer genes: recombinant antibody fragments for biological imaging. Q J Nucl Med 44(3):268–283
Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S et al (2001) 99mTc-labeled divalent and tetravalent CC49 single-chain Fv’s: novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med 42(10):1519–1527
Wittel UA, Jain M, Goel A, Chauhan SC, Colcher D, Batra SK (2005) The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol 32(2):157–164
Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY et al (1996) Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56(13):3055–3061
Dearling JL, Pedley RB (2007) Technological advances in radioimmunotherapy. Clin Oncol (R Coll Radiol) 19(6):457–469
Huhalov A, Chester KA (2004) Engineered single chain antibody fragments for radioimmunotherapy. Q J Nucl Med Mol Imaging 48(4):279–288
Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP et al (1996) (1996) Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2(9):979–984
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A et al (2004) A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res 64(17):6200–6206
Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff G, Goldenberg DM et al (1994) Initial clinical results with technetium-99 m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 73(3 Suppl):896–899
Behr TM, Goldenberg DM, Becker W (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 25(2):201–212
Luxton RW (1961) Radiation nephritis. A long-term study of 54 patients. Lancet 2(7214):1221–1224
Madrazo AA, Churg J (1976) Radiation nephritis. Chronic changes following moderate doses of radiation. Lab Invest 34(3):283–290
Pimm MV, Gribben SJ (1994) Prevention of renal tubule re-absorption of radiometal (indium-111) labelled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine. Eur J Nucl Med 21(7):663–665
Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL et al (1995) Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 55(17):3825–3834
Behr TM, Becker WS, Sharkey RM, Juweid ME, Dunn RM, Bair HJ et al (1996) Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 37(5):829–833
Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG et al (1993) Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 67(6):1437–1439
Garkavij M, Samarzija M, Ewers SB, Jakopovic M, Tezak S, Tennvall J (2005) Concurrent radiotherapy and tumor targeting with 111In-HMFG1-F(ab’)2 in patients with MUC1-positive non-small cell lung cancer. Anticancer Res 25(6C):4663–4671
Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F et al (2005) Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 11(19 Pt 2):7053s–7063s
Hong H, Sun J, Cai W (2008) Radionuclide-based cancer imaging targeting the carcinoembryonic antigen. Biomark Insights 3:435–451
Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP et al (2005) Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65(4):1471–1478
Osbourn JK, Field A, Wilton J, Derbyshire E, Earnshaw JC, Jones PT et al (1996) Generation of a panel of related human scFv antibodies with high affinities for human CEA. Immunotechnology 2(3):181–196
Green AJ, Johnson CJ, Adamson KL, Begent RH (2001) Mathematical model of antibody targeting: important parameters defined using clinical data. Phys Med Biol 46(6):1679–1693
Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK et al (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61(12):4750–4755
Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2(10):750–763
Richman CM, DeNardo SJ (2001) Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Crit Rev Oncol Hematol 38(1):25–35
Barratt-Boyes SM (1996) Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother 43(3):142–151
Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H et al (2006) Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. Int J Oncol 29(1):49–55
Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S et al (1998) Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17–23, 1996. Tumor Biol 19(Suppl 1):1–20
DeNardo SJ, Kramer EL, O’Donnell RT, Richman CM, Salako QA, Shen S et al (1997) Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 38(8):1180–1185
Schrier DM, Stemmer SM, Johnson T, Kasliwal R, Lear J, Matthes S et al (1995) High-dose 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a phase I trial. Cancer Res 55(23 Suppl):5921s–5924s
DeNardo SJ, Denardo GL (2006) Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 66(2 Suppl):S89–S95
Howell LP, DeNardo SJ, Levy NB, Lund J, Denardo GL (1995) Immunohistochemical staining of metastatic ductal carcinomas of the breast by monoclonal antibodies used in imaging and therapy: a comparative study. Int J Biol Markers 10(3):129–135
Peterson JA, Zava DT, Duwe AK, Blank EW, Battifora H, Ceriani RL (1990) Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule. Hybridoma 9(3):221–235
Kramer EL, DeNardo SJ, Liebes L, Kroger LA, Noz ME, Mizrachi H et al (1993) Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study. J Nucl Med 34(7):1067–1074
McEwan AJ, MacLean GD, Hooper HR, Sykes T, McQuarrie SA, Golberg L et al (1992) MAb 170H.82: an evaluation of a novel panadenocarcinoma monoclonal antibody labelled with 99Tcm and with 111In. Nucl Med Commun 13(1):11–19
Richman CM, DeNardo SJ, O’Donnell RT, Goldstein DS, Shen S, Kukis DL et al (1999) Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A. Clin Cancer Res 5(10 Suppl):3243s–3248s
O’Donnell RT, DeNardo SJ, Yuan A, Shen S, Richman CM, Lara PN et al (2001) Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res 7(6):1561–1568
DeNardo SJ, Richman CM, Albrecht H, Burke PA, Natarajan A, Yuan A et al (2005) Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clin Cancer Res 11(19 Pt 2):7187s–7194s
Albrecht H, Denardo GL, DeNardo SJ (2007) Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. Q J Nucl Med Mol Imaging 51(4):304–313
Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111(9):1287–1295
Amir E, Hughes S, Blackhall F, Thatcher N, Ostoros G, Timar J et al (2008) Targeting blood vessels for the treatment of non-small cell lung cancer. Curr Cancer Drug Targets 8(5):392–403
Israeli RS, Powell CT, Fair WR, Heston WD (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53(2):227–230
Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS et al (1994) Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54(24):6306–6310
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3(1):81–85
Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V et al (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57(17):3629–3634
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59(13):3192–3198
Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V et al (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58(18):4055–4060
Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22(13):2522–2531
Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23(21):4591–4601
Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G et al (1987) Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 6(8):2337–2342
Castellani P, Borsi L, Carnemolla B, Biro A, Dorcaratto A, Viale GL et al (2002) Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 161(5):1695–1700
Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A et al (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102(1):75–85
Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C et al (2009) Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin’s lymphoma patients. Blood 113(10):2265–2274
Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126–1136
Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463
Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R et al (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5(2):98–101
Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L et al (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 19(19):3918–3928
Srivastava S, Dadachova E (2001) Recent advances in radionuclide therapy. Semin Nucl Med 31(4):330–341
Humm JL (1986) Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 27(9):1490–1497
Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D et al (1997) Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon carcinoma. Int J Cancer 72(3):477–485
Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ et al (2004) Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 45(7):1224–1232
Nourigat C, Badger CC, Bernstein ID (1990) Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst 82(1):47–50
O’Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36(10):1902–1909
Richman CM, DeNardo SJ (2001) Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies. Crit Rev Oncol Hematol 38(1):25–35
Allen BJ (1999) Can alpha-immunotherapy succeed where other systemic modalities have failed? Nucl Med Commun 20(3):205–207
McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM et al (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25(9):1341–1351
Hartmann F, Horak EM, Garmestani K, Wu C, Brechbiel MW, Kozak RW et al (1994) Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res 54(16):4362–4370
Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW et al (2003) Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 101(12):5068–5075
Janssen ML, Pels W, Massuger LF, Oyen WJ, Boonstra H, Corstens FH et al (2003) Intraperitoneal radioimmunotherapy in an ovarian carcinoma mouse model: effect of the radionuclide. Int J Gynecol Cancer 13(5):607–613
Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR et al (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100(4):1233–1239
Bumol TF, Reisfeld RA (1982) Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A 79(4):1245–1249
Rizvi SM, Allen BJ, Tian Z, Goozee G, Sarkar S (2001) In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer. Colorectal Dis 3(5):345–353
Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P et al (2005) Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 4(12):1318–1324
Raja C, Graham P, Abbas Rizvi SM, Song E, Goldsmith H, Thompson J et al (2007) Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 6(6):846–852
Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS et al (2008) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49(1):30–38
Kassis AI, Harapanhalli RS, Adelstein SJ (1999) Strand breaks in plasmid DNA after positional changes of Auger electron-emitting iodine-125: direct compared to indirect effects. Radiat Res 152(5):530–538
Akabani G, Carlin S, Welsh P, Zalutsky MR (2006) In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol 33(3):333–347
Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578
Barbet J, Kraeber-Bodere F, Chatal JF (2008) What can be expected from nuclear medicine tomorrow? Cancer Biother Radiopharm 23(4):483–504
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S
Freudenberg LS, Jentzen W, Muller SP, Bockisch A (2008) Disseminated iodine-avid lung metastases in differentiated thyroid cancer: a challenge to 124I PET. Eur J Nucl Med Mol Imaging 35(3):502–508
Dunphy MP, Lewis JS (2009) Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 50(Suppl 1):106S–121S
Ferro-Flores G, de Murphy CA (2007) Current developments in SPECT/CT systems using 99mTc-radiopharmaceuticals. Rev Invest Clin 59(5):373–381
Goldenberg DM, Sharkey RM (2007) Novel radiolabeled antibody conjugates. Oncogene 26(25):3734–3744
Behr TM, Becker WS, Bair HJ, Klein MW, Stuhler CM, Cidlinsky KP et al (1995) Comparison of complete versus fragmented technetium-99 m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 36(3):430–441
Wegener WA, Petrelli N, Serafini A, Goldenberg DM (2000) Safety and efficacy of arcitumomab imaging in colorectal cancer after repeated administration. J Nucl Med 41(6):1016–1020
Lane DM, Eagle KF, Begent RH, Hope-Stone LD, Green AJ, Casey JL et al (1994) Radioimmunotherapy of metastatic colorectal tumors with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab’)2 antibodies. Br J Cancer 70(3):521–525
Fuster D, Maurel J, Muxi A, Setoain X, Ayuso C, Martin F et al (2003) Is there a role for (99 m)Tc-anti-CEA monoclonal antibody imaging in the diagnosis of recurrent colorectal carcinoma? Q J Nucl Med 47(2):109–115
Libutti SK, Alexander HR Jr, Choyke P, Bartlett DL, Bacharach SL, Whatley M et al (2001) A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 8(10):779–786
Jhanwar YS, Divgi C (2005) Current status of therapy of solid tumors. J Nucl Med 46(Suppl 1):141S–150S
Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24(5):823–834
Urbano N, Papi S, Ginanneschi M, De SR, Pace S, Lindstedt R et al (2007) Evaluation of a new biotin-DOTA conjugate for pretargeted antibody-guided radioimmunotherapy (PAGRIT). Eur J Nucl Med Mol Imaging 34(1):68–77
Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM et al (2000) Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med 41(1):131–140
Breitz HB, Fisher DR, Goris ML, Knox S, Ratliff B, Murtha AD et al (1999) Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm 14(5):381–395
Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C et al (2003) Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 9(10 Pt 2):3973S–3981S
Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L et al (2006) Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 47(2):247–255
Bagshawe KD, Sharma SK, Begent RH (2004) Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 4(11):1777–1789
Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L et al (2002) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumors. Br J Cancer 87(6):600–607
Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J et al (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 6(3):765–772
Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J et al (2006) A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 12(21):6509–6516
Liedert B, Bassus S, Schneider CK, Kalinke U, Lower J (2007) Safety of phase I clinical trials with monoclonal antibodies in Germany—the regulatory requirements viewed in the aftermath of the TGN1412 disaster. Int J Clin Pharmacol Ther 45(1):1–9
Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355(10):1018–1028
Kenter MJ, Cohen AF (2006) Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368(9544):1387–1391
Muller PY, Brennan FR (2009) Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 85(3):247–258
Department of Health (2006) Expert Scientific Group on phase one clinical trials: a consultation. Department of Health. 14-9-2006. Abstract
Hamoudeh M, Kamleh MA, Diab R, Fessi H (2008) Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 60(12):1329–1346
Franc BL, Acton PD, Mari C, Hasegawa BH (2008) Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J Nucl Med 49(10):1651–1663
Weber WA, Czernin J, Phelps ME, Herschman HR (2008) Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol 5(1):44–54
Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ et al (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21(15):2831–2842
Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK et al (2009) A phase I trial of radioimmunotherapy with 131I–A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res 15(13):4484–4492
Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T et al (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26(28):4572–4578
Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD et al (2008) Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7(4):496–501
McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM (2009) Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumor xenografts. Eur J Nucl Med Mol Imaging 36(1):81–93
Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J et al (2009) Development and characterization of clinical-grade 89Zr-Trastuzumab for HER2/neu ImmunoPET imaging. J Nucl Med 50(6):974–981
Perik PJ, Lub-de Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S et al (2006) Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24(15):2276–2282
Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG et al (2009) Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 50(1):123–131
DeNardo SJ, Richman CM, Goldstein DS, Shen S, Salako Q, Kukis DL et al (1997) Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. Anticancer Res 17(3B):1735–1744
Denardo GL, Raventos A, Hines HH, Scheibe PO, Macey DJ, Hays MT et al (1985) Requirements for a treatment planning system for radioimmunotherapy. Int J Radiat Oncol Biol Phys 11(2):335–348
Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40(2):37S–61S
Sgouros G, Chiu S, Pentlow KS, Brewster LJ, Kalaigian H, Baldwin B et al (1993) Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 34(9):1595–1601
Tagesson M, Ljungberg M, Strand SE (1996) A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system. Acta Oncol 35(3):367–372
Watson EE, Stabin MG, Siegel JA (1993) MIRD formulation. Med Phys 20(2 Pt 2):511–514
Bardies M, Myers MJ (1996) Computational methods in radionuclide dosimetry. Phys Med Biol 41(10):1941–1955
Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46(6):1023–1027
Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R et al (1989) Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7(8):1027–1038
Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Nelp WB et al (1990) High-dose radioimmunotherapy of B cell lymphomas. Front Radiat Ther Oncol 24:204–213
Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB et al (1993) Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329(17):1219–1224
Green AJ, Dewhurst SE, Begent RH, Bagshawe KD, Riggs SJ (1990) Accurate quantification of 131I distribution by gamma camera imaging. Eur J Nucl Med 16(4–6):361–365
Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM et al (2003) Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 44(1):67–76
Wahl RL (2003) The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol 30(2 Suppl 4):31–38
Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD et al (1993) Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329(7):459–465
Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D et al (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit Rev Oncol Hematol 39(1–2):181–194
Kwekkeboom D, Krenning EP, de Jong M (2000) Peptide receptor imaging and therapy. J Nucl Med 41(10):1704–1713
Cheson BD (2007) The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 21(5):841–854
Derenzini E, Musuraca G, Fanti S, Stefoni V, Tani M, Alinari L et al (2008) Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin’s lymphoma. Cancer 113(9):2496–2503
Green AJ, Francis RJ, Baig S, Begent RH (2008) Semiautomatic volume of interest drawing for (18)F-FDG image analysis-method and preliminary results. Eur J Nucl Med Mol Imaging 35(2):393–406
Flynn AA, Green AJ, Pedley RB, Boxer GM, Dearling J, Watson R et al (2002) A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer 94(4 Suppl):1249–1257
Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R et al (2001) Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res 61(12):4716–4722
Wong JY (2006) Basic immunology of antibody targeted radiotherapy. Int J Radiat Oncol Biol Phys 66(2 Suppl):S8–14
Sharkey RM, Goldenberg DM (2008) Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev 60(12):1407–1420
Boehm MK, Mayans MO, Thornton JD, Begent RH, Keep PA, Perkins SJ (1996) Extended glycoprotein structure of the seven domains in human carcinoembryonic antigen by X-ray and neutron solution scattering and an automated curve fitting procedure: implications for cellular adhesion. J Mol Biol 259(4):718–736
Chester KA, Begent RH, Robson L, Keep P, Pedley RB, Boden JA et al (1994) Phage libraries for generation of clinically useful antibodies. Lancet 343(8895):455–456
Blakey DC, Burke PJ, Davies DH, Dowell RI, Melton RG, Springer CJ et al (1995) Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumor disease. Biochem Soc Trans 23(4):1047–1050
Tolner B, Smith L, Begent RH, Chester KA (2006) Production of recombinant protein in Pichia pastoris by fermentation. Nat Protoc 1(2):1006–1021
Tolner B, Smith L, Begent RH, Chester KA (2006) Expanded-bed adsorption immobilized-metal affinity chromatography. Nat Protoc 1(3):1213–1222
Springer CJ, Dowell R, Burke PJ, Hadley E, Davis DH, Blakey DC et al (1995) Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 38(26):5051–5065
Boehm MK, Corper AL, Wan T, Sohi MK, Sutton BJ, Thornton JD et al (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J 346(Pt 2):519–528
Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA et al (2001) Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material. Br J Cancer 84(12):1671–1676
Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U et al (2005) Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res 11(2 Pt 1):814–825
Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J et al (2006) A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Clin Cancer Res 12(21):6509–6516
Acknowledgements
This was work was supported by Cancer Research UK, the UCL Experimental Cancer Medicine Centre, the UCL/KCL Comprehensive Cancer Imaging Centre, the UCL Cancer Institute Research Trust and in part by the NIHR UCLH Comprehensive Biomedical Centre.
Conflict of interest statement
No funds were received to produce this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dancey, G., Begent, R.H. & Meyer, T. Imaging in targeted delivery of therapy to cancer. Targ Oncol 4, 201–217 (2009). https://doi.org/10.1007/s11523-009-0119-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-009-0119-8